Di Nunno, Vincenzo; De Luca, Emmanuele; Buttigliero, Consuelo; Tucci, Marcello; Vignani, Francesca; Gatto, Lidia; Zichi, Clizia; Ardizzoni, Andrea; Di Maio, Massimo; Massari, Francesco*, Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2018, 129, pp. 124 - 132 [Scientific article]
Di Nunno, Vincenzo; De Luca, Emmanuele; Buttigliero, Consuelo; Tucci, Marcello; Vignani, Francesca; Gatto, Lidia; Zichi, Clizia; Ardizzoni, Andrea; Di Maio, Massimo; Massari, Francesco, Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2018, 129, pp. 124 - 132 [Scientific article]
Santoni M.; Massari F.; Di Nunno V.; Conti A.; Cimadamore A.; Scarpelli M.; Montironi R.; Cheng L.; Battelli N.; Lopez-Beltran A., Immunotherapy in renal cell carcinoma: latest evidence and clinical implications, «DRUGS IN CONTEXT», 2018, 7, Article number: 212528 , pp. 1 - 8 [Scientific article]Open Access
Bersanelli M.; Giannarelli D.; Castrignano P.; Fornarini G.; Panni S.; Mazzoni F.; Tiseo M.; Rossetti S.; Gambale E.; Rossi E.; Papa A.; Cortellini A.; Lolli C.; Ratta R.; Michiara M.; Milella M.; Luca E.D.; Soraru M.; Mucciarini C.; Atzori F.; Banna G.L.; Torre L.L.; Vitale M.G.; Massari F.; Rebuzzi S.E.; Facchini G.; Schinzari G.; Tomao S.; Bui S.; Vaccaro V.; Procopio G.; Giorgi U.D.; Santoni M.; Ficorella C.; Sabbatini R.; Maestri A.; Natoli C.; Tursi M.D.; Maio M.D.; Rapacchi E.; Pireddu A.; Sava T.; Lipari H.; Comito F.; Verzoni E.; Leonardi F.; Buti S., INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study, «IMMUNOTHERAPY», 2018, 10, pp. 1229 - 1239 [Scientific article]
Di Nunno V.; Santoni M.; Massari F., Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?, «THE LANCET ONCOLOGY», 2018, 19, pp. 437 - 437 [Scientific article]
Iacovelli R.; De Giorgi U.; Galli L.; Zucali P.; Nole F.; Sabbatini R.; Fraccon A.P.; Basso U.; Mosca A.; Atzori F.; Santini D.; Facchini G.; Fornarini G.; Pasini F.; Masini C.; Massari F.; Buti S.; Sava T.; Sacco C.; Ricotta R.; Sperduti I.; Tortora G.; Porta C., Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?, «CLINICAL GENITOURINARY CANCER», 2018, 16, pp. 355 - 359 [Scientific article]
Ghedini, Pietro*; Bossert, I.; Zanoni, L.; Ceci, F.; Graziani, T.; Castellucci, P.; Ambrosini, V.; Massari, F.; Nobili, E.; Melotti, B.; Musto, A.; Zoboli, S.; Antunovic, L.; Kirienko, M.; Chiti, A.; Mosconi, C.; Ardizzoni, A.; Golfieri, R.; Fanti, S.; Nanni, C., Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis, «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2018, 45, pp. 751 - 758 [Scientific article]
Cheng L.; Lopez-Beltran A.; Massari F.; Maclennan G.T.; Montironi R., Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine, «MODERN PATHOLOGY», 2018, 31, pp. 24 - 38 [Scientific article]
Cimadamore A.; Cheng M.; Santoni M.; Lopez-Beltran A.; Battelli N.; Massari F.; Galosi A.B.; Scarpelli M.; Montironi R., New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen, «FRONTIERS IN ONCOLOGY», 2018, 8, Article number: 653 , pp. 1 - 11 [Scientific article]Open Access
Bimbatti D.; Ciccarese C.; Fantinel E.; Sava T.; Massari F.; Bisogno I.; Romano M.; Porcaro A.; Brunelli M.; Martignoni G.; Mazzarotto R.; Artibani W.; Tortora G.; Iacovelli R., Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma, «UROLOGIC ONCOLOGY», 2018, 36, pp. 526 - 531 [Scientific article]
Montironi R.; Cimadamore A.; Gasparrini S.; Mazzucchelli R.; Santoni M.; Massari F.; Cheng L.; Lopez-Beltran A.; Scarpelli M., Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma, «EXPERT REVIEW OF ANTICANCER THERAPY», 2018, 18, pp. 685 - 693 [Scientific article]
Massari F.; Santoni M.; Di Nunno V.; Cimadamore A.; Battelli N.; Scarpelli M.; Cheng M.; Lopez-Beltran A.; Cheng L.; Montironi R., Quick steps toward precision medicine in renal cell carcinoma, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2018, 3, pp. 283 - 285 [Scientific article]
Di Nunno V.; Santoni M.; Cimadamore A.; Battelli N.; Massari F., Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560–9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step?, «EUROPEAN UROLOGY», 2018, 74, pp. 118 - 119 [Scientific article]
Massari F.; Di Nunno V., Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8, «EUROPEAN UROLOGY», 2018, 74, pp. 12 - 13 [Scientific article]
Di Nunno V.; Santoni M.; Massari F., Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405–15, «EUROPEAN UROLOGY», 2018, 74, pp. 50 - 50 [Scientific article]
